Skip to main content

COVID 19 Updates from RheumNow

Higher Rates of SARS-CoV-2 Seropositivity in the USA

The number of reporting cases of COVID-19 infection tends to underestimate the true prevalence of infection as only the more severe cases (e.g.,acute respiratory syndrome) get tested or go to the hospital.

Steroids and Tocilizumab in Cytokine Storm Syndrome

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receivin

RECOVERY Trial: Dexamethasone in COVID-19

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-da

Characteristics Underlying Mortal COVID-19 Outcomes

From January 1, 2020–May 18, 2020, approximately 1.3 million cases of coronavirus disease 2019 (COVID-19) and 83,000 COVID-19–associated deaths were reported in the United States.

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow.

Anti-Rheumatic Therapies for COVID-19 Infection

Since the onset of the COVID-19 pandemic numerous anti-rheumatic therapies have been proposed as being potentially beneficial.

Growing Risk of COVID Among Adolescents

The risk COVID-19 infection and mortality in the U.S. has been closely correlated with increasing age. However, recent data suggests that young adults (aged 18–25 years) have shown an increasing risk of COVID-19 infection since the pandemic began in March 2020.

Extrapulmonary Manifestations of COVID-19

A new article in Nature Medicine delineates how our understanding of COVID-19 infection has evolved over time, such that the infection outomes may be worsened by extrapulmonary manifestations; notably thrombotic, cardiac, renal, gastrointestinal hepatic, neurologic, and other complicatio

ICYMI: Protective Benefit of Colchicine in COVID-19 Infection

Editor's note: This article was originally published June 26, 2020 and is being shared again while RheumNow is on vacation in case you missed it. 

ICYMI: Faith

Editor's note: This blog was originally published June 3, 2020, and is being shared again while RheumNow is on vacation this week in case you missed it. 

ICYMI: Preventing COVID - Masks, Meters and Eyewear

Editor's note: This article originally appeared June 4, 2020, and is being shared again this week in case you missed it. 

ICYMI: Some Good Things, During the Time of COVID-19

Editor's note: This blog was originally published April 1, 2020, and is being shared again this week. 

Social

#ACR21 Ab#L03: B cell depletors and #COVID19 vax: ⭐️B cell count <40 around vax had lower response to vax, than 40+ B-cell, independent of RTX or BEL ▶️ Timing of vax around B cell return can improve response @Rheumnow https://t.co/1B7Bnb1QQu https://t.co/bKnfw6gD8O
2 years 5 months ago
Breakthrough COVID-19 in rheum pts: great data @rheum_covid B-cell depleting agents overrepresented, esp in hospitalization in fully vaccinated - but plenty of others Booster (& booster booster) vaccine doses + other mitigation badly needed! @rheum_cat #ACR21 ABSTL04 @RheumNow https://t.co/92Sn3mCwAi
David Liew @drdavidliew ( View Tweet )
2 years 5 months ago
#ACR21 L04 @rheumcat on #COVID19 in vaxed pts ▶️87 pts in @rheum_covid w/ ifn s/p full vax. 110 partial vax pts ⭐️25% (22/87) full vax pts hospitalized. 45% on BCDT. 8/22 hospitalized had lung disease, 5 no other co-morbidities. 5 deaths (23%). @RheumNow https://t.co/DB8C6jKvuU https://t.co/dxUwjTRxxb
2 years 5 months ago
#ACR21 #Abstr1541 Any tools to help differentiate MAS vs #COVID inflammatory response? Preliminary criteria showed Sensitivity: 79.6%; Specificity: 81.3% within 6 days admission. No Triglyceride/Fibrinogen compared to 2016 ACR-EULAR & 2004 HLH @RheumNow https://t.co/c7pHaVCr5S https://t.co/6irF64qizI
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 5 months ago
#ACR21 Abs#1536 #Vaccine uptake in people with #RheumaticDisease 👉🏼High uptake of vaccines in ~240 pts @BrighamWomens 👉🏼84% pts wanted the #COVID19 vaccine 👉🏼Physician recommendation was key determinant of uptake @RheumNow https://t.co/us0i5CW5Mi https://t.co/aLZmOPWFR3
Mrinalini Dey @DrMiniDey ( View Tweet )
2 years 5 months ago
🆕 Updated 2021 ACR Guidance for Adjusting Immunomodulatory Therapy with the COVID-19 Vaccine in Patients with Rheumatic & MSK Diseases Discussed at #ACR21 COVID-19 Hub! V4 Link: https://t.co/1SOR9yTQyF https://t.co/PKFKXpLofN
Mithu Maheswaranathan, MD @MithuRheum ( View Tweet )
2 years 5 months ago
#ACR21 Year In Review: Factors associated with #COVID deaths in pts with #RMD: ⛔️age, male, HTN/CVD, lung disease, steroid>10mg/d, ⬆️disease activity ⛔️RTX (OR: 4), SFZ (3.6), other IS (2.2), No DMARDs (2.1) vs MTX monotherapy as reference @RheumNow https://t.co/Zd6qXCtGLk https://t.co/YHBEelLqKB
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 5 months ago
Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
Richard Conway @RichardPAConway ( View Tweet )
2 years 5 months ago
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway @RichardPAConway ( View Tweet )
2 years 5 months ago
Important differences between vascular pathologies seen in #COVID19 and DIC by Dr. D McGonagle 👉Fibrinogen - normal/sl. ⬆ in PIC-assoc'd COVID19 vs. ⬇ in DIC sec to MAS @RheumNow #ACR21 #MedTwitter 📌https://t.co/DdmAhVIR51 https://t.co/Xw8LKaKcFd
2 years 5 months ago